Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Specification
The disclosure is objected to because paragraph 0013 line 20 it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim (s) 1 to 6 and 8 to 10 is/are rejected under 35 U.S.C. 102 as being unpatentable over by Tokuda et al (20100119956).
Regarding claim 1 and 5,
Nonaqueous electrolyte for secondary batteries with cycle characteristics [0022].
Where a fluorine-containing organic lithium salt is present [0064]. The electrolytic solution is a cyclic polyamine, which is in the family of a cyclic amine. Where the use of a capturing compound includes a heterocyclic ring in the list of examples they provided, where at least one of them have a plurality of carbon atoms and a plurality of nitrogen atoms [0711].
Tokuda further teaches the use of triazacycloalkanes such as… 1,5,9-triazacyclododecane [0711]. Tokuda is silent about an imaginary sphere diameter of the claimed compound. However, the imaginary sphere diameter is a physical characteristic of the molecular structure and cannot vary if the compound is the same and if is prepared and measured under the same conditions. One ordinary skill in the art would understand that the disclosed compound inherently exhibits the claimed property.
Regarding claim(s) 2 to 4 and 8 to 10,
Tokuda is silent about an imaginary sphere diameter of the claimed compound. However, each of claims 2-4 recite slightly different, but overlapping imaginary sphere diameters and claim 8-10 indicate that 1,5,9-triazacyclododecane can be used to meet the ranges. Therefor the teachings of Tokuda as applied to claims 1 and 5 above also anticipate these claims.
Regarding claim 6,
The concentration of these electrolytes is generally 0.5 mol/L or higher, preferably 0.6 mol/L or higher, more preferably 0.7 mol/L or higher. The upper limit thereof is generally 3 mol/L or lower, preferably 2 mol/L or lower, more preferably 1.8 mol/L or lower, especially preferably 1.5 mol/L or lower [0646].
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claim (s) 7 is/are rejected under 35 U.S.C. 103 as being unpatentable over by Tokuda et al (20100119956) as applied to claim 2 above, and further in view of PIJPERS (20160164125) and J Phys Chem A. 2017.
Regarding claim 7,
The use of the 1,4,7-triazonane which have three nitrogen atoms and three acetic acids.
Tokuda is silence about the compound 2,2',2"-(1,4,7-triazonane-1,4,7- triyl)triacetic acid but teaches the use of the genus chemical. PIJPERS further teaches the use of triazacyclononane as an electrolyte solution [0043]. In the same field of endeavor, chelators, article discloses how 1,4,7-Triazacyclononane-1,4,7-triacetic acid (NOTA) is a key bifunctional chelator utilized for the complexation of metal ions in radiopharmaceutical applications (Paragraph 1). It would have been obvious to one of ordinary skill in the art at the time the invention was made to use at least one capturing compound in the electrolyte solution the 2,2',2"-(1,4,7-triazonane-1,4,7- triyl)triacetic acid because of their potential in the chelation of the ions. The modification of it can be due to improving affinity or enhancing stability.
Conclusion
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.
Any inquiry concerning this communication should be directed to NICOLAS J ROSA BERRIOS at telephone number (571)270-1856.
Examiner interviews are available via a variety of formats. See MPEP § 713.01. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Alison Hindenlang can be reached on (571) 270-7001. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/Nicolas Rosa/
Examiner / Art Unit 1741
7/8/2026
/ALISON L HINDENLANG/Supervisory Patent Examiner, Art Unit 1741
Prosecution Insights